Abstract 400: NCI's CPTAC Phase III, proteogenomic analysis of additonal cancer types

Abstract The Clinical Proteomics Tumor Analysis Consortium (CPTAC) is a National Cancer Institute initiative that seeks to uncover the molecular basis of cancer using a proteogenomic approach to study prospective cancer specimens. Leidos Biomed provides an infrastructure for supporting the collection of high quality biospecimens and data, in addition to project and subcontract management for the program. CPTAC applies the understanding of the molecular basis of cancer to identify biomarker candidates. Phase II of CPTAC, completed in 2016, collected over 500 cases from breast, colon and ovarian patients. In early 2016, CPTAC Phase III began to collect and analyze 200 cases of each of ten additional cancers. The goal is to collect 200 qualified cases of five to six tumor types over a five-year period, although the program is currently accruing from ten. The study entails collection and pathology evaluation of biospecimens, high-quality clinical data and images from clinical sites around the world. A biorepository evaluates and processes the biospecimens, sending nucleic acids to a sequencing center and tissues to proteomics groups. Data are combined and analyzed by translational centers. Genomic data are made available to the research community through the NCI Genomic Data Commons. Proteomic data are made available through the Data Coordinating Center. We report here on progress in collection of tissues and clinical data, and use of biorepository, proteomics and genomics and analysis centers. Citation Format: Linda I. Hannick. NCI's CPTAC Phase III, proteogenomic analysis of additonal cancer types [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 400. doi:10.1158/1538-7445.AM2017-400